Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Effects of Multiple Therapeutic and Supratherapeutic Doses of Cebranopadol on Cardiac Repolarization in Healthy Subjects

NCT03958123 is registered in ClinicalTrials.gov with Tris Pharma, Inc. as lead sponsor.

NCT NCT03958123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03958123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Effects of Multiple Therapeutic and Supratherapeutic Doses of Cebranopadol on Cardiac Repolarization in Healthy Subjects
Lead sponsor
Tris Pharma, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 10, 2013
Completion date
November 27, 2013
Enrollment
171 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetic, prolonged qtc interval